Von Willebrand Factor As a Biological Sensor of Blood Flow in Percutaneous Cardiac Procedure

University Hospital, Lille500 enrolled

Overview

The WITAVI study was designed to explore the kinetic and associated outcome of Von Willebrand Factor-multimerizaton defects associated with devices in cardiovascular diseases.

This study was designed to understand the Von Willebrand Factor (VWF) abnormalities observed in association with implantation of different devices in cardiovascular diseases (percutaneous valve replacement and circulatory support devices). The main objective of the study was to describe the time-course of VWF abnormalities onset/offset during implantation of devices in cardiovascular diseases. Adult patients \> 18 years who need a CF-LVAD or trans-aortic valve implantation are included in this cohort; Blood samples are obtained just before procedures

Study Type

OBSERVATIONAL

Enrollment

500

Conditions

Heart Failure Aortic Stenosis

Interventions

cardiac devicesDEVICE

patients receiving mechanical circulatory support or undergoing trans aortic valve replacement

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patients \> 18 years who need a mechanical circulatory support due to advanced heart failure or undergoing trans-aortic-valve-replacement to treat aortic stenosis. * Informed consent of the patient or support person in case of disability at baseline (patient intubated and ventilated) Exclusion Criteria: * Patient with a known severe bleeding disorder * Patient refusal or environment * Minor patients * Pregnant women

Locations (1)

Lille University Hospital

Lille, France

RECRUITING

Outcomes

Primary Outcomes

Von Willebrand factor (VWF) multimer defects

VWF multimeric analysis is performed by electrophoresis. The results of HMW-multimers are expressed as the relative amount of the largest multimers (mer\>15) of the sample compared with those of the normal pooled plasma (NPP standard human plasma Siemens healthcare diagnostics, Marburg, Germany, coefficient of variation=11%) present on each gel. 4-6 With this method the HMW-multimer ratio is defined as the HMW-multimers (\>15-mer) in patient plasma sample divided by HMW-multimers in normal pool plasma, the HMW-multimer ratio of normal pooled plasma is 1 (by definition) and an HMW-multimer defect is defined as a reduced HMW-multimer-ratio (\<1).

Time frame: 180 minutes after device implantation

Secondary Outcomes

platelet function analyser- ADP (PFA-ADP) closure time

The PFA test is initially performed with the Collagen/Epinepherine membrane. A normal Col/ADP closure time (\<180 seconds) excludes the presence of a significant platelet function defect.

Time frame: 5, 15,30, 60 minutes; day 1 , day 7 after device implantation

Central Contacts

Sophie Susen, MD, PhD

CONTACT

33320445937 sophie.susen@chru-lille.fr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.